Associate Professor of Medicine, University of Chicago Medicine
Hematology
Dr. Olatoyosi Odenike, MD
Olatoyosi Odenike practices Hematology. He went to University of Illinois College of Medicine at Chicago. University of Illinois College of Medicine at Chicago has a rank of 49 in research and a 85 in primary care He over the years received 2 awards: "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Olatoyosi Odenike is a published doctor and has 43 publications published. The lastest was: 'Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, doubl...' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory Acute myeloid leukaemia (VALOR): a randomised, controlled, doubl...
- Allo-SCT for myelofibrosis: reversing the Chronic phase in the JAK inhibitor era?
- Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of Myeloproliferative neoplasms.
- A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced Myeloid neoplasia.
- Geriatric assessment to predict survival in older allogeneic hematopoietic Celltransplantation recipients.
- A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory Leukemia and high-risk myelodysplastic syndromes.
- Phase II Study Of The Oral MEK Inhibitor Selumetinib In Advanced Acute Myeloid Leukemia (AML): A University Of Chicago Phase II Consortium Trial.
- A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (...
- Immune reconstitution after combined haploidentical and umbilical cord blood transplant.
- Age-related differences in Disease characteristics and clinical outcomes in polycythemia vera.
- Influence of related donor age on outcomes after peripheral blood stem Cell transplantation.
- Treatment of relapsed chronic lymphocytic Leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B st...
- Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic Malignancies.
- A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant Diseases.
- Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
- Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid enGraftment, low GVHD, and durable remissions.
- High Dose Cytarabine and Mitoxantrone: An Effective Induction Regimen for High-Risk Acute Myeloid Leukemia (AML).
- Allogeneic stem cell transplant in renal failure: enGraftment and prolonged survival, but high incidence of neurologic toxicity.
- The dawn of the molecular era of the Myelodysplastic syndromes.
- An integrated genomic approach to the assessment and treatment of Acute myeloid leukemia.
- Gene mutations, epigenetic dysregulation, and personalized therapy in Myeloid neoplasia: are we there yet?
- Emerging role of the histone deacetylase inhibitor romidepsin in hematologic Malignancies.
- Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem Cell transplant: reduced clearance at high ...
- Treatment of therapy-related Myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
- Leukaemogenesis: more than mutant genes.
- Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous Leukemia.
- DNA repair genes, electromagnetic fields and susceptibility to Acute leukemia?
- Histone deacetylase inhibitor romidepsin has differential activity in core binding factor Acute myeloid leukemia.
- Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic Cell transplantation.
- Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid Leukemia--Cancer and Leukemia gro...
- A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory Acute leukemia.
- A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and Acute myeloid leukemia.
- Successful autologous stem cell collection in patients with chronic myeloid Leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL express...
- Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbaZone (3-AP) in combination with high dose cytarabine in patients ...
- Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic Cell transplantation.
- Successful allogeneic transplantation of patients with suspected prior invasive mold infection.
- Primary myelofibrosis (PMF), post Polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Co...
- Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic Cell transplantation.
- International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with Myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatm...
- Conventional and new treatment options for myelofibrosis with Myeloid metaplasia.
- Myelofibrosis with Myeloid metaplasia: where is the biology leading us?
- Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced Acute myeloid leukemia and myelodysplastic syndrome.
Schools
University Of Ibadan College Of Medicine
University Ill Hospital
University Chicago Hospital
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- Coventry Health Care
- Coventry Health Care of Illinois PPO
- Health and Life PPO
- Platinum PPO
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- HealthLink PPO
- HealthSmart
- Humana
- Medicaid
- Medicare MCR
- Meritain Health
- MultiPlan PPO
- PHCS Network PPO
- Pekin Insurance
- Priority Health
- Sagamore Plus
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Chicago -
University of Illinois College of Medicine at Chicago -
University of Ibadan
Hospital
-
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1194887646 | |
| NPPES Provider LastName | ODENIKE | |
| NPPES Provider FirstName | OLATOYOSI | |
| NPPES Provider ZIPCode | 605276686 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 208.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1194887646 |
| Last Name Of The Provider | ODENIKE |
| First Name Of The Provider | OLATOYOSI |
| View All |
Similar Doctors
|
Dr. Wendy Stock, MD |
|
|
Dr. Renee H. Jacobs, MD |
|
|
Dr. Joseph M. Baron, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James E. Hannigan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dorothy Sipkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzanne D. Conzen, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Richard L. Schilsky, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Lucy A. Godley, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Olufunmailyao Olopade, MD |
|
|
Dr. Christopher K. Daugherty, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Ezra E. Cohen, MD |
|
|
Brittany Beach
This Doctor is OpenDoctor Recommended.
|